Research ArticleSpondyloarthritis
Open Access
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials
Atul Deodhar, Xenofon Baraliakos, Marina Magrey, Lianne S. Gensler, Amit V. Thorat, Surya Kiran Pemmaraju, Mary Jane Cadatal and Peter Nash
The Journal of Rheumatology August 2024, 51 (8) 772-780; DOI: https://doi.org/10.3899/jrheum.2023-1198
Atul Deodhar
1A. Deodhar, MD, Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA;
Xenofon Baraliakos
2X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany;
Marina Magrey
3M. Magrey, MD, Case Western Reserve University School of Medicine, University Hospitals, Cleveland, Ohio, USA;
Lianne S. Gensler
4L.S. Gensler, MD, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco, California, USA;
Amit V. Thorat
5A.V. Thorat, MD, MHA, MPharmMed, Pfizer Australia, Sydney, Australia;
Surya Kiran Pemmaraju
6S.K. Pemmaraju, MSc, Pfizer, Chennai, India;
Mary Jane Cadatal
7M.J. Cadatal, MSc, Pfizer, Manila, Philippines;
Peter Nash
8P. Nash, MBBS, Griffith University, Sunshine Coast, Nathan, Australia.

Data supplements
Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 8
1 Aug 2024
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials
Atul Deodhar, Xenofon Baraliakos, Marina Magrey, Lianne S. Gensler, Amit V. Thorat, Surya Kiran Pemmaraju, Mary Jane Cadatal, Peter Nash
The Journal of Rheumatology Aug 2024, 51 (8) 772-780; DOI: 10.3899/jrheum.2023-1198
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials
Atul Deodhar, Xenofon Baraliakos, Marina Magrey, Lianne S. Gensler, Amit V. Thorat, Surya Kiran Pemmaraju, Mary Jane Cadatal, Peter Nash
The Journal of Rheumatology Aug 2024, 51 (8) 772-780; DOI: 10.3899/jrheum.2023-1198





